May 20, 2020 / 6:17 AM / 7 days ago

BRIEF-Biophytis Receives Approval From FAMHP To Initiate Cova Trial

May 20 (Reuters) - Biophytis SA:

* BIOPHYTIS RECEIVES APPROVAL FROM THE BELGIAN REGULATORY AGENCY (FAMHP) TO INITIATE COVA

* COVA IS CLINICAL TRIAL WITH SARCONEOS (BIO101) FOR TREATMENT OF PATIENTS WITH COVID19 RELATED RESPIRATORY FAILURE

* HIS PHASE 2/3 CLINICAL TRIAL IS EXPECTED TO START IN BELGIUM IN THE COMING WEEKS

* FIRST PART OF STUDY WILL RECRUIT COVID-19 PATIENTS WHO HAVE DEVELOPED SEVERE RESPIRATORY SYMPTOMS WITHIN LAST 7 DAYS

* SECOND PART OF COVA TRIAL WILL INCLUDE AT LEAST 180 COVID-19 PATIENTS

* WORKED WITH ITS SUPPLIERS TO ENSURE THAT IT HAS ACCESS TO SUFFICIENT SARCONEOS (BIO101) TO COMPLETE MULTI-CENTER COVA TRIAL PROGRAM AS PLANNED Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below